Table 4

Selected ongoing studies with elotuzumab- and daratumumab-containing regimens in previously untreated high-risk smoldering MM

StudyPhaseTreatment
NCT02316106 (Centaurus) 2 Daratumumab as single agent 
NCT02279394 2 Elotuzumab and lenalidomide ± dexamethasone 
NCT01441973 2 Elotuzumab as single agent 
StudyPhaseTreatment
NCT02316106 (Centaurus) 2 Daratumumab as single agent 
NCT02279394 2 Elotuzumab and lenalidomide ± dexamethasone 
NCT01441973 2 Elotuzumab as single agent 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal